Strickler, J. H., Zemla, T., Ou, F.-S., Cercek, A., Wu, C., Sanchez, F. A., … Bekaii-Saab, T. (2019). Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial. In ANNALS OF ONCOLOGY (Vol. 30). Barcelona, SPAIN: OXFORD UNIV PRESS.

Strickler, J. H., T. Zemla, F. -. S. Ou, A. Cercek, C. Wu, F. A. Sanchez, J. Hubbard, et al. “Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial.” In ANNALS OF ONCOLOGY, Vol. 30. OXFORD UNIV PRESS, 2019.

Strickler JH, Zemla T, Ou F-S, Cercek A, Wu C, Sanchez FA, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019.

Strickler, J. H., et al. “Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial.” ANNALS OF ONCOLOGY, vol. 30, OXFORD UNIV PRESS, 2019.

Strickler JH, Zemla T, Ou F-S, Cercek A, Wu C, Sanchez FA, Hubbard J, Jaszewski B, Bandel L, Schweitzer B, Niedzwiecki D, Kemeny N, Boland PM, Ng K, Bekaii-Saab T. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019.